UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
International journal of hematology, ISSN 0925-5710, 3/2019, Volume 109, Issue 3, pp. 366 - 368
Medicine & Public Health | Hematology | Oncology | Life Sciences & Biomedicine | Science & Technology | Asian Continental Ancestry Group | Pyrazoles - administration & dosage | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Japan | Pyrimidines - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Female | Male | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Pyrazoles - adverse effects | Analysis | Cancer | Lymphocytes B | Index Medicus
Journal Article
Cancer science, ISSN 1347-9032, 07/2015, Volume 106, Issue 7, pp. 896 - 901
Daily dosing schedule | phase I study | hematological malignancy | STAT3 inhibitor | OPB‐51602 | Phase I study | OPB-51602 | Hematological malignancy | Life Sciences & Biomedicine | Oncology | Science & Technology | Peripheral Nervous System Diseases - chemically induced | Phosphorylation | Nausea - chemically induced | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - toxicity | Maximum Tolerated Dose | Multiple Myeloma - drug therapy | Protein Processing, Post-Translational - drug effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Antineoplastic Agents - pharmacokinetics | STAT3 Transcription Factor - antagonists & inhibitors | STAT3 Transcription Factor - metabolism | Lymphoma, Non-Hodgkin - drug therapy | Transcription | Leukemia | Multiple myeloma | Myeloma | Peripheral neuropathy | Signal transduction | Bone marrow | Lactic acidosis | Neutropenia | Thrombocytopenia | Leukopenia | Hematology | Myeloid leukemia | Diarrhea | Nausea | Patients | Lymphoma | Studies | Lymphopenia | Antitumor activity | Lactic acid | Pharmacokinetics | Acidosis | Acute myeloid leukemia | Pharmaceuticals | Tumors | Index Medicus | Original
Journal Article
Cancer science, ISSN 1347-9032, 03/2018, Volume 109, Issue 3, pp. 794 - 802
peripheral T‐cell lymphoma | cutaneous T‐cell lymphoma | Japanese patients | E7777 | phase I study | peripheral T-cell lymphoma | cutaneous T-cell lymphoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Skin Neoplasms - drug therapy | Drug Administration Schedule | Administration, Oral | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Drug Resistance, Neoplasm | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Lymphoma, T-Cell, Cutaneous - drug therapy | Young Adult | Diphtheria Toxin - therapeutic use | Maximum Tolerated Dose | Interleukin-2 - administration & dosage | Adult | Female | Aged | Infusions, Intravenous | Recombinant Fusion Proteins - administration & dosage | Cohort Studies | Interleukins | T cells | Non-Hodgkin's lymphomas | Cytotoxicity | Kinases | Lipase | Proteins | Hypokalemia | CD25 antigen | Fusion protein | Diphtheria toxin | Pharmaceutical industry | Drug dosages | Appetite | Alanine | Hyponatremia | Cytokines | Research funding | Amino acid sequence | Fatigue | Diphtheria | Lymphoma | Studies | Hospitals | Lymphopenia | Medical prognosis | Alanine transaminase | Antitumor activity | Pharmacokinetics | Tumors | Index Medicus | Original
Journal Article
International journal of hematology, ISSN 0925-5710, 06/2019, Volume 109, Issue 6, pp. 657 - 664
Life Sciences & Biomedicine | Hematology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Recurrence | Humans | Middle Aged | Male | Treatment Outcome | Asian Continental Ancestry Group | Multiple Myeloma - drug therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Aged, 80 and over | Adult | Female | Aged | Infusions, Intravenous | Antigens, CD19 - immunology | Lymphoma, B-Cell - drug therapy | Monoclonal antibodies | Transplantation | Lymphomas | Leukemia | Hematopoietic stem cells | Chronic lymphatic leukemia | CD19 antigen | Leukopenia | Toxicity | Multiple myeloma | Stem cell transplantation | Pharmacology | Lymphatic leukemia | Dosage | Patients | Lymphoma | Hemopoiesis | Anticancer properties | Infusion | Antitumor agents | Lymphocytes B | Stem cells | Pharmacokinetics | Neutropenia | B-cell lymphoma | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 17, pp. 2103 - 2109
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Recurrence | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - surgery | Lymphoma, Large B-Cell, Diffuse - pathology | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Rituximab | Male | Nitrogen Mustard Compounds - adverse effects | Remission Induction | Stem Cell Transplantation | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adult | Female | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Index Medicus
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 9/2015, Volume 61, Issue 5, pp. 719 - 729
ARTICLES AND COMMENTARIES | Resolved HBV infection | Rituximab | HBV DNA monitoring | Preemptive antiviral therapy | HBV reactivation | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Lymphoma, B-Cell - complications | Prospective Studies | Antiviral Agents - therapeutic use | Humans | Middle Aged | Hepatitis B - virology | Hepatitis B - epidemiology | Male | Lymphoma, B-Cell - epidemiology | DNA, Viral - blood | Hepatitis B - complications | Antiviral Agents - adverse effects | Hepatitis B - drug therapy | Hepatitis B virus - genetics | Female | Lymphoma, B-Cell - virology | Aged | Antiviral agents | Care and treatment | Dosage and administration | Hepatitis B virus | Research | Hepatitis B | Hepatitis | Antigens | Surveillance | Lymphoma | Risk factors | Deoxyribonucleic acid--DNA | Index Medicus
Journal Article
International journal of hematology, ISSN 0925-5710, 06/2017, Volume 105, Issue 6, pp. 792 - 804
Dasatinib | Imatinib | CML | Tyrosine kinase inhibitor | Japan | Life Sciences & Biomedicine | Hematology | Science & Technology | Japan - epidemiology | Follow-Up Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Survival Rate | Disease-Free Survival | Asian Continental Ancestry Group | Dasatinib - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Imatinib Mesylate - administration & dosage | Adult | Female | Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Antimitotic agents | Tyrosine | Medical colleges | Medical research | Resveratrol | Clinical trials | Medicine, Experimental | Chronic myeloid leukemia | Antineoplastic agents | Hands | Slopes | Cornea | Effectiveness | Myeloid leukemia | Leukemia | Pleural effusion | Patients | Survival | Health care delivery | Safety | Index Medicus
Journal Article
International journal of hematology, ISSN 0925-5710, 1/2016, Volume 103, Issue 1, pp. 86 - 94
B cell malignancies | Covalent BTK inhibitor | Medicine & Public Health | Hematology | Oncology | Safety | Japanese | Ibrutinib | Life Sciences & Biomedicine | Science & Technology | Recurrence | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Enzyme Inhibitors - administration & dosage | Enzyme Inhibitors - pharmacokinetics | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Pyrazoles - pharmacokinetics | Lymphoma, B-Cell - drug therapy | Pyrazoles - adverse effects | Enzyme Inhibitors - adverse effects | Pyrimidines - administration & dosage | Treatment Outcome | Asian Continental Ancestry Group | Maximum Tolerated Dose | Pyrazoles - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Protein-Tyrosine Kinases - antagonists & inhibitors | Medical colleges | Pneumonia | Safety and security measures | Anemia | Bacterial pneumonia | Lymphomas | Bilirubin | Cancer | Index Medicus
Journal Article
International journal of hematology, ISSN 0925-5710, 12/2019, Volume 110, Issue 6, pp. 709 - 722
Medicine & Public Health | Hematology | Acute lymphoblastic leukemia | Oncology | Inotuzumab ozogamicin | Asian | Relapsed/refractory | Life Sciences & Biomedicine | Science & Technology | Inotuzumab Ozogamicin - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications | Salvage Therapy - adverse effects | Hepatic Veno-Occlusive Disease - etiology | Standard of Care | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Inotuzumab Ozogamicin - adverse effects | Neoplasm, Residual | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Asian Continental Ancestry Group | Salvage Therapy - standards | Adult | Female | Remission Induction - methods | Salvage Therapy - methods | Medical colleges | Transplantation | Acute lymphocytic leukemia | Analysis | Hematopoietic stem cells | Acute lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Stem cell transplantation | International standardization | Lymphatic leukemia | Patients | Subgroups | Hemopoiesis | Randomization | Lymphocytes B | Stem cells | Remission | Safety | Index Medicus
Journal Article
Beilstein journal of organic chemistry, ISSN 1860-5397, 09/2019, Volume 15, Issue 1, pp. 2204 - 2212
Journal Article
Cancer science, ISSN 1347-9032, 12/2016, Volume 107, Issue 12, pp. 1785 - 1790
ibrutinib | Efficacy | mantle cell lymphoma | safety | overall response rate | Life Sciences & Biomedicine | Oncology | Science & Technology | Recurrence | Pyrazoles - therapeutic use | Humans | Middle Aged | Lymphoma, Mantle-Cell - pathology | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Lymphoma, Mantle-Cell - mortality | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Pyrazoles - adverse effects | Pyrimidines - administration & dosage | Lymphoma, Mantle-Cell - drug therapy | Treatment Outcome | Protein Kinase Inhibitors - administration & dosage | Retreatment | Pyrazoles - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Medical research | Relapse | Anemia | Medicine, Experimental | Development and progression | Lymphomas | Censorship | Diseases | Hematology | Toxicity | Research & development--R&D | Oral administration | Diarrhea | Patients | Lymphoma | Stomatitis | Chemotherapy | Mantle cell lymphoma | Cell cycle | Sepsis | Safety | Pharmaceuticals | Neutropenia | Index Medicus | Original
Journal Article